[Skip to Navigation]
Sign In
Invited Commentary
September 2018

Sarcopenia—A New Frontier in the Management Care of Patients With Borderline Resectable Pancreatic Cancer

Author Affiliations
  • 1Professorial Surgical Unit, Department of Surgery, Trinity College Dublin, Trinity Centre for Health Sciences, Dublin, Ireland
JAMA Surg. 2018;153(9):816. doi:10.1001/jamasurg.2018.1006

Pancreatic cancer is the fourth most common cause of cancer-related mortality in Europe.1 Despite increased awareness, most patients continue to present with advanced disease. There has been minimal improvement in survival rates over the past 30 years, with overall 5-year survival remaining less than 8%.2 While these disappointing results are due to a multitude of host and treatment variables, it is apparent that, for a significant number of patients, poor nutritional and performance status are limiting factors to treatment choice, delivery, and tolerance.

Add or change institution